Evidence map›Paper›PMID 23500609›Full record

Trial reportGynecologic oncology2013

Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.

Florian Heitz, Andreas du Bois, Philipp Harter, Dirk Lubbe, Christian Kurzeder, Ignace Vergote, Marie Plante, Jacobus Pfisterer, AGO study group, NCIC-CTG study group and 1 more

Abstract readClinical Trial, Phase IClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Gynecologic oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Meta-analysis of the effects of beta blocker on survival time in cancer patients.Journal of cancer research and clinical oncology · 2014
    Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Stress Hormones: Emerging Targets in Gynecological Cancers.Frontiers in cell and developmental biology · 2021
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Florian HeitzKliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Department of Gynecology and Gynecologic Oncology, Henricistrasse 92, Essen, Germany. florian.heitz@gmx.net
Andreas du Bois
Philipp Harter
Dirk Lubbe
Christian Kurzeder
Ignace Vergote
Marie Plante
Jacobus Pfisterer
AGO study group
NCIC-CTG study group
EORTC-GCG study group
Kliniken Essen-Mitte · DEClinical Research Center Kiel · DEHôtel-Dieu de Québec · CAPhilipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRetrospective analyses suggest that the treatment with beta blocker improves survival in patients with breast cancer and melanoma. The aim of this study was to investigate the impact of medication with beta blocker in patients with recurrent ovarian cancer.

methodsIncluded patients received treatment within two prospective clinical trials: AGO-OVAR 2.4 phase I trial (carboplatin/gemcitabine; N=25, protocol AGO-OVAR 2.4) and AGO led intergroup phase III trial (carboplatin vs carboplatin/gemcitabine; N=356, protocol AGO-OVAR 2.5, EORTC-GCG, NCIC CTG). Concurrent medication was documented after every cycle and thorough monitoring was conducted.

resultsDuring the studies 38 patients (9.97%) received a beta blocker as co-medication. Patients treated with beta blockers were significantly older than patients not treated with beta blockers. Response rates to chemotherapy were not different between patients treated with beta blockers and those who were not. After a median follow-up of 17 months, 349 (91.6%) patients had progressive disease and 267 (70.1%) patients had died. No difference in median progression-free survival (7.79 vs 7.62 months (p=0.95)) and overall survival (21.2 vs 17.3 months (p=0.18)) was recorded for patients treated with and without beta blocker. In multivariate analyses including age, platinum free-interval, study treatment and ECOG performance status beta blocker treatment was not associated with a significant impact on progression-free survival (HR: 0.92; 95% CI: 0.65-1.31; p=0.65) and overall survival (HR:0.74; 95%CI: 0.49-1.11; p=0.15).

conclusionsIn this series of recurrent platinum-sensitive ovarian cancer patients it could not be confirmed whether beta blocker treatment was associated with better or worse outcome.

Indexed as

Adrenergic beta-AntagonistsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinDeoxycytidineDisease-Free SurvivalFemaleFollow-Up StudiesGemcitabineHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsYoung AdultAdrenergic beta-AntagonistsCarboplatinDeoxycytidineGemcitabine

Identifiers

PMID23500609
OpenAlexW1963760152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.